

Registered number: 06103708

COMPANIES HOUSE

Biotech/Pharma Validation Limited

Unaudited

Abbreviated accounts

for the year ended 31 March 2012

THURSDAY



A1FXDXMX

A09

23/08/2012

#146

COMPANIES HOUSE

Biotech/Pharma Validation Limited

Contents

	Page
Accountants' report	1
Balance sheet	2
Notes to the abbreviated accounts	3

The following pages do not form part of the statutory financial statements

Biotech/Pharma Validation Limited

The following reproduces the text of the Chartered accountants' report in respect of the company's annual financial statements, from which the abbreviated accounts (set out on pages 2 to 3) have been prepared

Chartered accountants' report to the board of directors on the preparation of the unaudited statutory financial statements of Biotech/Pharma Validation Limited for the year ended 31 March 2012


In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Biotech/Pharma Validation Limited for the year ended 31 March 2012 which comprise the Profit and loss account, the Balance sheet and the related notes from the company's accounting records and from information and explanations you have given to us

As a member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at icaew.com/regulations

This report is made solely to the Board of directors of Biotech/Pharma Validation Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Biotech/Pharma Validation Limited and state those matters that we have agreed to state to them in this report in accordance with AAF 2/10 as detailed at icaew.com/compilation. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Biotech/Pharma Validation Limited and its Board of directors, as a body, for our work or for this report.

It is your duty to ensure that Biotech/Pharma Validation Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the company's assets, liabilities, financial position and profit. You consider that Biotech/Pharma Validation Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or review of the financial statements of Biotech/Pharma Validation Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.



Reeves & Co LLP
Chartered Accountants
37 St Margaret's Street
Canterbury
Kent
CT1 2TU

15 August 2012

Biotech/Pharma Validation Limited
Registered number: 06103708

Abbreviated balance sheet
as at 31 March 2012

	Note	£	2012 £	£	2011 £
Current assets					
Debtors	2	43,739		9,910	
Cash at bank		14,456		21,922	
		<u>58,195</u>		<u>31,832</u>	
Creditors. amounts falling due within one year	3	<u>(20,827)</u>		<u>(19,678)</u>	
Net current assets			37,368		12,154
Net assets			37,368		12,154
Capital and reserves					
Called up share capital	4		2		2
Profit and loss account			<u>37,366</u>		<u>12,152</u>
Shareholders' funds			37,368		12,154

The directors consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at 31 March 2012 and of its profit for the year then ended in accordance with the requirements of sections 394 and 395 of the Act and which otherwise comply with the requirements of the Companies Act 2006 relating to the financial statements so far as applicable to the company

The abbreviated accounts, which have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006, were approved and authorised for issue by the board and were signed on its behalf on 14 August 2012



A Nye
Director

The notes on page 3 form part of these financial statements

Biotech/Pharma Validation Limited

Notes to the abbreviated accounts for the year ended 31 March 2012

1. Accounting policies

1.1 Basis of preparation of financial statements

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

1.2 Cash flow

The financial statements do not include a Cash flow statement because the company, as a small reporting entity, is exempt from the requirement to prepare such a statement under the Financial Reporting Standard for Smaller Entities (effective April 2008)

1.3 Turnover

Turnover comprises revenue recognised by the company in respect of goods and services supplied during the year, exclusive of Value Added Tax and trade discounts

1.4 Pensions

The company operates a defined contribution pension scheme and the pension charge represents the amounts payable by the company to the fund in respect of the year

2. Debtors

Included within other debtors due within one year is an advance to Mr A Nye, a director, amounting to £23,268 (2011 - £nil) The overdrawn directors loan account was cleared on 6 April 2012 as a dividend of £25,000 was declared

3. Creditors

Amounts falling due within one year

Included within other creditors is a loan account from the Directors of £nil (2011 - £144)

4 Share capital

	2012 £	2011 £
Allotted, called up and fully paid		
1 Ordinary share of £1	1	1
1 'A' Share share of £1	1	1
	2	2